Search

Your search keyword '"Walter, Annette"' showing total 161 results
Start Over Author "Walter, Annette"
161 results on '"Walter, Annette"'

1. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling

Author

Graham, Keith, Lienau, Philip, Bader, Benjamin, Prechtl, Stefan, Naujoks, Jan, Lesche, Ralf, Weiske, Joerg, Kuehnlenz, Julia, Brzezinka, Krzysztof, Potze, Lisette, Zanconato, Francesca, Nicke, Barbara, Montebaur, Anna, Bone, Wilhelm, Golfier, Sven, Kaulfuss, Stefan, Kopitz, Charlotte, Pilari, Sabine, Steuber, Holger, Hayat, Sikander, Kamburov, Atanas, Steffen, Andreas, Schlicker, Andreas, Buchgraber, Philipp, Braeuer, Nico, Font, Nuria Aiguabella, Heinrich, Tobias, Kuhnke, Lara, Nowak-Reppel, Katrin, Stresemann, Carlo, Steigemann, Patrick, Walter, Annette O., Blotta, Simona, Ocker, Matthias, Lakner, Ashley, von Nussbaum, Franz, Mumberg, Dominik, Eis, Knut, Piccolo, Stefano, and Lange, Martin

Published
2024
Full Text
View/download PDF

2. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Author

Kindler, Hedy L, Novello, Silvia, Bearz, Alessandra, Ceresoli, Giovanni L, Aerts, Joachim G J V, Spicer, James, Taylor, Paul, Nackaerts, Kristiaan, Greystoke, Alastair, Jennens, Ross, Calabrò, Luana, Burgers, Jacobus A, Santoro, Armando, Cedrés, Susana, Serwatowski, Piotr, Ponce, Santiago, Van Meerbeeck, Jan P, Nowak, Anna K, Blumenschein, George, Jr, Siegel, Jonathan M, Kasten, Linda, Köchert, Karl, Walter, Annette O, Childs, Barrett H, Elbi, Cem, Hassan, Raffit, and Fennell, Dean A

Published
2022
Full Text
View/download PDF

5. Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I / Rho-GTPase signaling

Author

Graham, Keith, primary, Lienau, Philip, additional, Bader, Benjamin, additional, Prechtl, Stefan, additional, Naujoks, Jan, additional, Lesche, Ralf, additional, Kuehnlenz, Julia, additional, Brzezinka, Krzysztof, additional, Potze, Lisette, additional, Zanconato, Francesca, additional, Nicke, Barbara, additional, Montebaur, Anna, additional, Bone, Wilhelm, additional, Golfier, Sven, additional, Kaulfuss, Stefan, additional, Kopitz, Charlotte, additional, Pilari, Sabine, additional, Steuber, Holger, additional, Hayat, Sikander, additional, Kamburov, Atanas, additional, Steffen, Andreas, additional, Schlicker, Andreas, additional, Buchgraber, Philipp, additional, Braeuer, Nico, additional, Font, Nuria Aiguabella, additional, Heinrich, Tobias, additional, Kuhnke, Lara, additional, Nowak-Reppel, Katrin, additional, Stresemann, Carlo, additional, Steigemann, Patrick, additional, Walter, Annette Olga, additional, Blotta, Simona, additional, Ocker, Matthias, additional, Lakner, Ashley, additional, Mumberg, Dominik, additional, Eis, Knut, additional, Piccolo, Stefano, additional, and Lange, Martin, additional

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Author

Tjin Tham Sjin, Robert, primary, Lee, Kwangho, primary, Walter, Annette O., primary, Dubrovskiy, Aleksandr, primary, Sheets, Michael, primary, Martin, Thia St., primary, Labenski, Matthew T., primary, Zhu, Zhendong, primary, Tester, Richland, primary, Karp, Russell, primary, Medikonda, Aravind, primary, Chaturvedi, Prasoon, primary, Ren, Yixuan, primary, Haringsma, Henry, primary, Etter, Jeff, primary, Raponi, Mitch, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Westlin, William F., primary, Petter, Russell C., primary, Allen, Andrew, primary, and Singh, Juswinder, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

10. Data from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Materials and Methods from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Materials and Methods and Supplementary Figure Legends from In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Author

Tjin Tham Sjin, Robert, primary, Lee, Kwangho, primary, Walter, Annette O., primary, Dubrovskiy, Aleksandr, primary, Sheets, Michael, primary, Martin, Thia St., primary, Labenski, Matthew T., primary, Zhu, Zhendong, primary, Tester, Richland, primary, Karp, Russell, primary, Medikonda, Aravind, primary, Chaturvedi, Prasoon, primary, Ren, Yixuan, primary, Haringsma, Henry, primary, Etter, Jeff, primary, Raponi, Mitch, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Westlin, William F., primary, Petter, Russell C., primary, Allen, Andrew, primary, and Singh, Juswinder, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 4 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Author

Walter, Annette O., primary, Sjin, Robert Tjin Tham, primary, Haringsma, Henry J., primary, Ohashi, Kadoaki, primary, Sun, Jing, primary, Lee, Kwangho, primary, Dubrovskiy, Aleksandr, primary, Labenski, Matthew, primary, Zhu, Zhendong, primary, Wang, Zhigang, primary, Sheets, Michael, primary, St Martin, Thia, primary, Karp, Russell, primary, van Kalken, Dan, primary, Chaturvedi, Prasoon, primary, Niu, Deqiang, primary, Nacht, Mariana, primary, Petter, Russell C., primary, Westlin, William, primary, Lin, Kevin, primary, Jaw-Tsai, Sarah, primary, Raponi, Mitch, primary, Van Dyke, Terry, primary, Etter, Jeff, primary, Weaver, Zoe, primary, Pao, William, primary, Singh, Juswinder, primary, Simmons, Andrew D., primary, Harding, Thomas C., primary, and Allen, Andrew, primary

Published
2023
Full Text
View/download PDF

22. Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)

Author

Hümmert, Martin W, primary, Stern, Carlotta, additional, Paul, Friedemann, additional, Duchow, Ankelien, additional, Bellmann-Strobl, Judith, additional, Ayzenberg, Ilya, additional, Schwake, Carolin, additional, Kleiter, Ingo, additional, Hellwig, Kerstin, additional, Jarius, Sven, additional, Wildemann, Brigitte, additional, Senel, Makbule, additional, Berthele, Achim, additional, Giglhuber, Katrin, additional, Luessi, Felix, additional, Grothe, Matthias, additional, Klotz, Luisa, additional, Schülke, Rasmus, additional, Gingele, Stefan, additional, Faiss, Jürgen H, additional, Walter, Annette, additional, Warnke, Clemens, additional, Then Bergh, Florian, additional, Aktas, Orhan, additional, Ringelstein, Marius, additional, Stellmann, Jan-Patrick, additional, Häußler, Vivien, additional, Havla, Joachim, additional, Pellkofer, Hannah, additional, Kümpfel, Tania, additional, Kopp, Bruno, additional, and Trebst, Corinna, additional

Published
2023
Full Text
View/download PDF

23. Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Author

Hümmert, Martin W., primary, Bütow, Franziska, additional, Tkachenko, Daria, additional, Ayzenberg, Ilya, additional, Pakeerathan, Thivya, additional, Hellwig, Kerstin, additional, Klotz, Luisa, additional, Häußler, Vivien, additional, Stellmann, Jan-Patrick, additional, Warnke, Clemens, additional, Goereci, Yasemin, additional, Etgen, Thorleif, additional, Luessi, Felix, additional, Bronzlik, Paul, additional, Gingele, Stefan, additional, Lauenstein, Ann-Sophie, additional, Kleiter, Ingo, additional, Rommer, Paulus S., additional, Paul, Friedemann, additional, Bellmann-Strobl, Judith, additional, Duchow, Ankelien, additional, Then Bergh, Florian, additional, Pul, Refik, additional, Walter, Annette, additional, Pellkofer, Hannah, additional, Kümpfel, Tania, additional, Pompsch, Mosche, additional, Kraemer, Markus, additional, Albrecht, Philipp, additional, Aktas, Orhan, additional, Ringelstein, Marius, additional, Senel, Makbule, additional, Giglhuber, Katrin, additional, Berthele, Achim, additional, Jarius, Sven, additional, Wildemann, Brigitte, additional, and Trebst, Corinna, additional

Published
2023
Full Text
View/download PDF

24. sj-docx-1-msj-10.1177_13524585231151212 – Supplemental material for Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)

Author

Hümmert, Martin W, Stern, Carlotta, Paul, Friedemann, Duchow, Ankelien, Bellmann-Strobl, Judith, Ayzenberg, Ilya, Schwake, Carolin, Kleiter, Ingo, Hellwig, Kerstin, Jarius, Sven, Wildemann, Brigitte, Senel, Makbule, Berthele, Achim, Giglhuber, Katrin, Luessi, Felix, Grothe, Matthias, Klotz, Luisa, Schülke, Rasmus, Gingele, Stefan, Faiss, Jürgen H, Walter, Annette, Warnke, Clemens, Then Bergh, Florian, Aktas, Orhan, Ringelstein, Marius, Stellmann, Jan-Patrick, Häußler, Vivien, Havla, Joachim, Pellkofer, Hannah, Kümpfel, Tania, Kopp, Bruno, and Trebst, Corinna

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585231151212 for Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study) by Martin W Hümmert, Carlotta Stern, Friedemann Paul, Ankelien Duchow, Judith Bellmann-Strobl, Ilya Ayzenberg, Carolin Schwake, Ingo Kleiter, Kerstin Hellwig, Sven Jarius, Brigitte Wildemann, Makbule Senel, Achim Berthele, Katrin Giglhuber, Felix Luessi, Matthias Grothe, Luisa Klotz, Rasmus Schülke, Stefan Gingele, Jürgen H Faiss, Annette Walter, Clemens Warnke, Florian Then Bergh, Orhan Aktas, Marius Ringelstein, Jan-Patrick Stellmann, Vivien Häußler, Joachim Havla, Hannah Pellkofer, Tania Kümpfel, Bruno Kopp and Corinna Trebst in Multiple Sclerosis Journal

Published
2023
Full Text
View/download PDF

25. Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

Author

Santin, Alessandro D, primary, Vergote, Ignace, additional, González-Martín, Antonio, additional, Moore, Kathleen, additional, Oaknin, Ana, additional, Romero, Ignacio, additional, Diab, Sami, additional, Copeland, Larry J, additional, Monk, Bradley J, additional, Coleman, Robert L, additional, Herzog, Thomas J, additional, Siegel, Jonathan, additional, Kasten, Linda, additional, Schlicker, Andreas, additional, Schulz, Anke, additional, Köchert, Karl, additional, Walter, Annette O, additional, Childs, Barrett H, additional, Elbi, Cem, additional, and Bulat, Iurie, additional

Published
2022
Full Text
View/download PDF

27. 3.3 Body and Time Module

Author

Kleiner, Konrad, primary, Martínkova, Irena Parry, additional, Lenz, Elisabeth, additional, and Walter, Annette, additional

Published
2017
Full Text
View/download PDF

28. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.

Author

Santin, Alessandro D., Vergote, Ignace, González-Martín, Antonio, Moore, Kathleen, Oaknin, Ana, Romero, Ignacio, Diab, Sami, Copeland, Larry J., Monk, Bradley J., Coleman, Robert L., Herzog, Thomas J., Siegel, Jonathan, Kasten, Linda, Schlicker, Andreas, Schulz, Anke, Köchert, Karl, Walter, Annette O., Childs, Barrett H., Elbi, Cem, and Bulat, Iurie

Published
2023
Full Text
View/download PDF

29. Abstract ND04: BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy

Author

Gradl, Stefan, primary, Lee, Sooncheol, additional, Lange, Martin, additional, Wu, Xiaoyun, additional, Goldoni, Silvia, additional, Lewis, Timothy, additional, Kopitz, Charlotte, additional, Garvie, Colin, additional, Lienau, Philip, additional, Hoyt, Stephanie, additional, Seidel, Henrik, additional, Kaulfuss, Stephan, additional, Ellermann, Manuel, additional, de Waal, Luc, additional, Tersteegen, Adrian, additional, Golfier, Sven, additional, Suelzle, Detlev, additional, Hegele-Hartung, Christa, additional, Carr, James, additional, Brookfield, Frederick, additional, Bruening, Michael, additional, Berthold, Melanie, additional, Jourdan, Thibaud, additional, Schenone, Monica, additional, Gao, Galen, additional, McGaunn, Joseph, additional, Wengner, Antje, additional, Aquilanti, Elisa, additional, Siegel, Franziska, additional, Garrido, Marine, additional, Walter, Annette, additional, Genvresse, Isabelle, additional, Cherniack, Andrew, additional, Schreiber, Stuart, additional, Eis, Knut, additional, Eheim, Ashley, additional, Meyerson, Matthew, additional, and Greulich, Heidi, additional

Published
2022
Full Text
View/download PDF

30. Abstract 2663: Preclinical profiling of BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy

Author

Goldoni, Silvia, primary, Lange, Martin, additional, Kopitz, Charlotte, additional, Kaulfuss, Stefan, additional, Golfier, Sven, additional, Tersteegen, Adrian, additional, Bunse, Stefanie, additional, Berthold, Melanie, additional, Jordan, Thibaud, additional, Lienau, Philip, additional, Siegel, Franziska, additional, Walter, Annette, additional, Seidel, Henrik, additional, Aquilanti, Elisa, additional, Baker, Andrew, additional, Wu, Xiaoyun, additional, Lee, Sooncheol, additional, Gradl, Stefan, additional, di Tomaso, Emmanuelle, additional, Meyerson, Matthew, additional, Eis, Knut, additional, Eheim, Ashley, additional, and Greulich, Heidi, additional

Published
2022
Full Text
View/download PDF

31. Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease

Author

Hümmert, Martin, Schöppe, Louisa, Bellmann-Strobl, Judith, Siebert, Nadja, Paul, Friedemann, Duchow, Ankelien, Pellkofer, Hannah, Kümpfel, Tania, Havla, Joachim, Jarius, Sven, Wildemann, Brigitte, Berthele, Achim, Bergh, Florian, Pawlitzki, Marc, Klotz, Luisa, Kleiter, Ingo, Stangel, Martin, Gingele, Stefan, Weber, Martin, Faiss, Juergen, Pul, Refik, Walter, Annette, Zettl, Uwe, Senel, Makbule, Stellmann, Jan-Patrick, Häußler, Vivien, Hellwig, Kerstin, Ayzenberg, Ilya, Aktas, Orhan, Ringelstein, Marius, Schreiber-Katz, Olivia, Trebst, Corinna, Department of Neurology, Hannover Medical School, Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] (CEMEREM), Hôpital de la Timone [CHU - APHM] (TIMONE)-Centre de résonance magnétique biologique et médicale (CRMBM), and Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background and Objectives To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Methods In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. Results Two hundred twelve patients (80% women, median age 50 [19-83] years, median disease duration 7 [0-43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0-8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for €59,574 (95% CI 51,225-68,293 or US dollars [USD] 70,297, 95% CI 60,445-80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65-0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%)

Published
2022
Full Text
View/download PDF

33. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders

Author

Kümpfel, Tania, Thiel, Sandra, Meinl, Ingrid, Ciplea, Andrea I., Bayas, Antonios, Hoffmann, Frank, Hofstadt-van Oy, Ulrich, Hoshi, Muna, Kluge, Jakob, Ringelstein, Marius, Aktas, Orhan, Stoppe, Muriel, Walter, Annette, Weber, Martin S., Ayzenberg, Ilya, and Hellwig, Kerstin

Subjects
Adult, Multiple Sclerosis, Neuromyelitis Optica, Pregnancy Outcome, Antibodies, Monoclonal, Humanized, Article, Cohort Studies, Pregnancy Complications, Pregnancy, Germany, Humans, Immunologic Factors, Female, Rituximab
Abstract

Objective To report pregnancy outcomes and disease activity (DA) in women with MS, neuromyelitis optica spectrum disorders (NMOSDs), and other neuroimmunologic diseases (ONID) after treatment with rituximab (RTX)/ocrelizumab (OCR) 12 months before or during pregnancy. Methods Data were collected in the German MS and pregnancy registry and centers from the Neuromyelitis Optica Study Group. Sixty-eight known outcomes of 88 pregnancies from 81 women (64 MS, 10 NMOSD, and 7 ONID) were included and stratified in 3 exposure groups: >6M-group = RTX/OCR >6 but ≤12 months before the last menstrual period (LMP) (n = 8)

Published
2020

36. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Author

Hassan, Raffit, primary, Blumenschein, George R., additional, Moore, Kathleen N., additional, Santin, Alessandro D., additional, Kindler, Hedy L., additional, Nemunaitis, John J., additional, Seward, Shelly M., additional, Thomas, Anish, additional, Kim, Stella K., additional, Rajagopalan, Prabhu, additional, Walter, Annette O., additional, Laurent, Dirk, additional, Childs, Barrett H., additional, Sarapa, Nenad, additional, Elbi, Cem, additional, and Bendell, Johanna C., additional

Published
2020
Full Text
View/download PDF

38. Abstract 4816: Anetumab ravtansine has monotherapy efficacy in mesothelin positive patient-derived NSCLC tumor models and in a syngeneic tumor model in immunocompetent mice

Author

Sommer, Anette, primary, Lejeune, Pascale, additional, Hoff, Sabine, additional, Walter, Annette O., additional, Berndt, Sandra, additional, Roese, Lars, additional, Schlicker, Andreas, additional, Wick, Michael J., additional, Elbi, Cem, additional, Mumberg, Dominik, additional, and Schatz, Christoph, additional

Published
2019
Full Text
View/download PDF

39. Anti CD20 Therapies and Pregnancy in Neuroimmunological Disorders – A Case Series from Germany (P4.2-094)

Author

Kuempfel, Tania, primary, Thiel, Sandra, additional, Meinl, Ingrid, additional, Bayas, Antonios, additional, Ciplea, Andrea, additional, Hoffmann, Frank, additional, Oy, Ulrich Hofstadt-van, additional, Hoshi, Muna-Miriam, additional, Neubert, Antje, additional, Ringelstein, Marius, additional, Aktas, Orhan, additional, Stoppe, Muriel, additional, Bergh, Florian Then, additional, Tackenberg, Bjorn, additional, Walter, Annette, additional, Weber, Martin, additional, Gold, Ralf, additional, and Hellwig, Kerstin, additional

Published
2019
Full Text
View/download PDF

40. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity

Author

Postel-Vinay, Sophie, primary, Herbschleb, Karin, additional, Massard, Christophe, additional, Woodcock, Victoria, additional, Soria, Jean-Charles, additional, Walter, Annette O., additional, Ewerton, Flavio, additional, Poelman, Martine, additional, Benson, Neil, additional, Ocker, Matthias, additional, Wilkinson, Gary, additional, and Middleton, Mark, additional

Published
2019
Full Text
View/download PDF

42. Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.

Author

Adjei, Alex A., primary, Bekaii-Saab, Tanios S., additional, Berlin, Jordan, additional, Philip, Philip Agop, additional, Mercade, Teresa Macarulla, additional, Walter, Annette, additional, Cupit, Lisa, additional, Liu, Rong, additional, Fields, Scott Z., additional, and Holynskyj, Ariadna, additional

Published
2018
Full Text
View/download PDF

43. Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer

Author

Hassan, Raffit, primary, Wang, Ding, additional, Wrangle, John, additional, Thomas, Anish, additional, Byars, Angus, additional, Asschert, Lianne, additional, Atienza, Rolando, additional, Rajagopalan, Prabhu, additional, Walter, Annette, additional, Zhang, Jun, additional, Sarapa, Nenad, additional, and Kindler, Hedy, additional

Published
2018
Full Text
View/download PDF

44. The discovery of tetrahydro-β-carbolines as inhibitors of the kinesin Eg5

Author

Nathan Brammeier, Walter Annette O, Duhl David, Dirksen E. Bussiere, Paul A. Barsanti, Weibo Wang, Zhi-Jie Ni, and Eric J. Martin

Subjects
Models, Molecular, Molecular model, medicine.drug_class, Clinical Biochemistry, Allosteric regulation, Kinesins, Pharmaceutical Science, Carboxamide, Crystallography, X-Ray, Biochemistry, Structure-Activity Relationship, Allosteric Regulation, Cell Line, Tumor, Drug Discovery, medicine, Animals, Humans, Structure–activity relationship, Enzyme Inhibitors, Solid tumor, Molecular Biology, Binding Sites, Drug discovery, Chemistry, Organic Chemistry, High-Throughput Screening Assays, Rats, Beta Carbolines, Molecular Medicine, Kinesin, Carbolines
Abstract

A series of tetrahydro-beta-carbolines were identified by HTS as inhibitors of the kinesin Eg5. Molecular modeling and medicinal chemistry techniques were employed to explore the SAR for this series with a focus of removing potential metabolic liabilities and improving cellular potency.

Published
2010
Full Text
View/download PDF

45. 4-(1H-Indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors

Author

Weiping Jia, Walter Annette O, Cornelia Bellamacina, Song Lin, Mika Lindvall, Asha Yabannavar, Cynthia M. Shafer, and Thomas G. Gesner

Subjects
Indazoles, Molecular model, Stereochemistry, Chemistry, Pharmaceutical, Clinical Biochemistry, Molecular Conformation, Pharmaceutical Science, Cell Cycle Proteins, Pyrimidinones, Non-specific serine/threonine protein kinase, Protein Serine-Threonine Kinases, Biochemistry, Inhibitory Concentration 50, Structure-Activity Relationship, chemistry.chemical_compound, Drug Discovery, Humans, Pyrimidone, Enzyme Inhibitors, Molecular Biology, chemistry.chemical_classification, Indazole, Binding Sites, Molecular Structure, Bicyclic molecule, biology, Organic Chemistry, Enzyme, Models, Chemical, chemistry, Enzyme inhibitor, Drug Design, Benzene derivatives, biology.protein, Molecular Medicine, Caco-2 Cells
Abstract

A series of 4-(4-hydroxyphenyl)-6-phenylpyrimidin-2(1H)-ones were identified by HTS as inhibitors of CDC7. Molecular modeling and medicinal chemistry techniques were employed to explore the SAR for this series with a focus on removing potential metabolic liabilities and improving cellular potency.

Published
2008
Full Text
View/download PDF

46. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

Author

Krepler, Clemens, primary, Sproesser, Katrin, additional, Brafford, Patricia, additional, Beqiri, Marilda, additional, Garman, Bradley, additional, Xiao, Min, additional, Shannan, Batool, additional, Watters, Andrea, additional, Perego, Michela, additional, Zhang, Gao, additional, Vultur, Adina, additional, Yin, Xiangfan, additional, Liu, Qin, additional, Anastopoulos, Ioannis N., additional, Wubbenhorst, Bradley, additional, Wilson, Melissa A., additional, Xu, Wei, additional, Karakousis, Giorgos, additional, Feldman, Michael, additional, Xu, Xiaowei, additional, Amaravadi, Ravi, additional, Gangadhar, Tara C., additional, Elder, David E., additional, Haydu, Lauren E., additional, Wargo, Jennifer A., additional, Davies, Michael A., additional, Lu, Yiling, additional, Mills, Gordon B., additional, Frederick, Dennie T., additional, Barzily-Rokni, Michal, additional, Flaherty, Keith T., additional, Hoon, Dave S., additional, Guarino, Michael, additional, Bennett, Joseph J., additional, Ryan, Randall W., additional, Petrelli, Nicholas J., additional, Shields, Carol L., additional, Terai, Mizue, additional, Sato, Takami, additional, Aplin, Andrew E., additional, Roesch, Alexander, additional, Darr, David, additional, Angus, Steve, additional, Kumar, Rakesh, additional, Halilovic, Ensar, additional, Caponigro, Giordano, additional, Jeay, Sebastien, additional, Wuerthner, Jens, additional, Walter, Annette, additional, Ocker, Matthias, additional, Boxer, Matthew B., additional, Schuchter, Lynn, additional, Nathanson, Katherine L., additional, and Herlyn, Meenhard, additional

Published
2017
Full Text
View/download PDF

47. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

Author

Bahleda, Rastislav, primary, Grilley-Olson, Juneko E, additional, Govindan, Ramaswamy, additional, Barlesi, Fabrice, additional, Greillier, Laurent, additional, Perol, Maurice, additional, Ray-Coquard, Isabelle, additional, Strumberg, Dirk, additional, Schultheis, Beate, additional, Dy, Grace K, additional, Zalcman, Gérard, additional, Weiss, Glen J, additional, Walter, Annette O, additional, Kornacker, Martin, additional, Rajagopalan, Prabhu, additional, Henderson, David, additional, Nogai, Hendrik, additional, Ocker, Matthias, additional, and Soria, Jean-Charles, additional

Published
2017
Full Text
View/download PDF

49. P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma

Author

Hassan, Raffit, primary, Jennens, Ross, additional, Van Meerbeeck, Jan, additional, Nemunaitis, John, additional, Blumenschein, George, additional, Fennell, Dean, additional, Kindler, Hedy, additional, Novello, Silvia, additional, Walter, Annette, additional, Serpico, Danila, additional, Siegel, Jonathan, additional, Holynskyj, Ariadna, additional, Childs, Barrett, additional, and Elbi, Cem, additional

Published
2017
Full Text
View/download PDF

50. The role of social sustainability in building assessment.

Author

Stender, Marie and Walter, Annette

Subjects
SUSTAINABLE buildings, SOCIAL sustainability, SOCIAL ecology, STAKEHOLDERS, SOCIAL indicators
Abstract

Can social sustainability be built? What are the challenges and potential for incorporating the concept of social sustainability into the assessment of building projects? Theoretical approaches to social sustainability are examined for the ways it is applied in practice by building industry stakeholders. A fundamental question is whether and how social sustainability can be measured, assessed and certified in the construction or renewal of housing and neighbourhoods. In addition to physical and functional indicators, it is suggested that certification systems (e.g. the Deutsche Gesellschaft für Nachhaltiges Bauen - DGNB) should also reward social initiatives. A framework was developed involving 12 indicators grouped three overarching themes: social cohesion; participatory processes; and accessibility to living opportunities. A collaborative case study project involving two Danish social housing neighbourhoods examines how social sustainability indicators could be integrated into the application of certification systems such as the DGNB and whether the certification system can be improved by integrating social and organizational aspects with the existing criteria for physical and functional layout. It is found that certifications must take the housing complex or neighbourhood's relationship with the surrounding city into account, as well as its development over time and flexibility towards future needs. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results